Press release
Metastatic Colorectal Cancer Pipeline and Clinical Trials Assessment (2023) | Companies- G1Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shangha
Metastatic Colorectal Cancer Pipeline
The Metastatic Colorectal Cancer Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Metastatic Colorectal Cancer clinical trials studies, Metastatic Colorectal Cancer NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Metastatic Colorectal Cancer, licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.
To explore more information on the latest breakthroughs in Metastatic Colorectal Cancer Pipeline treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
• Over 140+ Metastatic Prostate Cancer companies are evaluating 140+ Metastatic Colorectal Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Colorectal Cancer market would significantly increase market revenue.
• The leading Metastatic Colorectal Cancer companies are working in the market such as G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others
• Emerging Metastatic Colorectal Cancer Pipeline Therapies in various stages of development include Oxaliplatin, Leucovorin, Bevacizumab, Encorafenib, Binimetinib, Cetuximab, Aflibercept, FOLFIRI, and others.
• In March 2022, ALX Oncology Inc. in collaboration with Merck Sharp & Dohme Corp. and Eli Lilly and Company will initiate a Phase II Study (With Safety run-in) of ALX148 in Combination with Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer. This is an open-label, multi-center, single-arm phase II clinical trial (with safety run-in) evaluating the combination of ALX148, cetuximab, and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer who have progressed on at least 2 lines of systemic therapy. A subset of patients will undergo study-related biopsies. There will be a safety run-in stage followed by a dose expansion stage. Patients in both stages will continue to receive study therapy until disease progression according to RECIST v1.1. The trial is currently in Recruiting stage and is expected to be completed by March 2026.
• In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
For further information, refer to the detailed Metastatic Colorectal Cancer Unmet Needs, Metastatic Colorectal Cancer Market Drivers, and Metastatic Colorectal Cancer Market Barriers, click here for Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Colorectal Cancer Emerging Drugs Profile
• Trilaciclib: G1 Therapeutics
• Famitinib: Jiangsu Hengrui Medicine
• CMAB009: Mabpharm Limited
• Trastuzumab Deruxtecan: Daiichi Sankyo
• SCO-101: Scandion Oncology
• BEY 1107: BeyondBio
• Etrumadenant: Arcus Biosciences
Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 140+ Metastatic Colorectal Cancer companies that are developing Metastatic Colorectal Cancer therapies. The Metastatic Colorectal Cancer companies which have their Metastatic Colorectal cancer drug candidates in the most advanced stage, i.e. phase III include G1 Therapeutics.
Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
• Metastatic Colorectal Cancer Assessment by Product Type
• Metastatic Colorectal Cancer by Stage and Product Type
• Metastatic Colorectal Cancer Assessment by Route of Administration
• Metastatic Colorectal Cancer by Stage and Route of Administration
• Metastatic Colorectal Cancer Assessment by Molecule Type
• Metastatic Colorectal Cancer by Stage and Molecule Type
Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Colorectal Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Some of the companies in the Metastatic Colorectal Cancer Therapeutics Market include-
G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others
Dive deep into rich insights for drugs for Metastatic Colorectal Cancer Pipeline, click here @ Metastatic Colorectal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Metastatic Colorectal Cancer Pipeline Report
• Coverage- Global
• Metastatic Colorectal Cancer Companies- G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others
• Metastatic Colorectal Cancer Pipeline Therapies- Oxaliplatin, Leucovorin, Bevacizumab, Encorafenib, Binimetinib, Cetuximab, Aflibercept, FOLFIRI, and others.
• Metastatic Colorectal Cancer Pipeline Therapies- Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Metastatic Colorectal Cancer Mergers and acquisitions, Metastatic Colorectal Cancer Licensing Activities @ Metastatic Colorectal Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Metastatic Colorectal Cancer Executive Summary
3. Metastatic Colorectal cancer: Overview
4. Metastatic Colorectal Cancer Pipeline Therapeutics
5. Metastatic Colorectal Cancer Therapeutic Assessment
6. Metastatic Colorectal cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Trilaciclib: G1 Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Trastuzumab Deruxtecan: Daiichi Sankyo
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I/II)
17. NKTR-255: Nektar Therapeutics
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Talimogene Laherparepvec: Amgen
21. Drug profiles in the detailed report…..
22. Preclinical and Discovery Stage Products
23. PCS11T: Processa Pharmaceuticals
24. Drug profiles in the detailed report…..
25. Inactive Products
26. Metastatic Colorectal cancer Key Companies
27. Metastatic Colorectal cancer Key Products
28. Metastatic Colorectal cancer- Unmet Needs
29. Metastatic Colorectal cancer- Market Drivers and Barriers
30. Metastatic Colorectal cancer- Future Perspectives and Conclusion
31. Metastatic Colorectal cancer Analyst Views
32. Metastatic Colorectal cancer Key Companies
33. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Colorectal Cancer Pipeline and Clinical Trials Assessment (2023) | Companies- G1Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shangha here
News-ID: 3077708 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
